• PDF / 882,095 Bytes
• 9 Pages / 595.276 x 790.866 pts Page_size
• 75 Downloads / 188 Views

DOWNLOAD

REPORT

ORIGINAL RESEARCH ARTICLE

Determining Which of Several Simultaneously Administered Vaccines Increase Risk of an Adverse Event Shirley V. Wang1   · Kristina Stefanini1 · Edwin Lewis2 · Sophia R. Newcomer3 · Bruce Fireman4 · Matthew F. Daley3,5 · Jason M. Glanz3,6 · Jonathan Duffy7 · Eric Weintraub7 · Martin Kulldorff1

© Springer Nature Switzerland AG 2020

Abstract Introduction  Childhood immunization schedules often involve multiple vaccinations per visit. When increased risk of an adverse event is observed after simultaneous (same-day) vaccinations, it can be difficult to ascertain which triggered the adverse event. This methods paper discusses a systematic process to determine which of the simultaneously administered vaccine(s) are most likely to have caused an observed increase in risk of an adverse event. Methods  We use an example from the literature where excess risk of seizure was observed 1 day after vaccination, but same-day vaccination patterns made it difficult to discern which vaccine(s) may trigger the adverse event. We illustrate the systematic identification process using a simulation that retained the observed pattern of simultaneous vaccination in an empirical cohort of vaccinated children. We simulated “true” effects for diphtheria–tetanus–acellular pertussis (DTaP) and pneumococcal conjugate (PCV) on risk of seizure the day after vaccination. We varied the independent and interactive effects of vaccines (on the multiplicative scale). After applying the process to simulated data, we evaluated risk of seizure 1 day after vaccination in the empirical cohort. Results  In all simulations, we were able to determine which vaccines contributed to excess risk. In the empirical data, we narrowed the association with seizure from all vaccines in the schedule to three likely candidates, DTaP, PCV, and/or Haemophilus influenzae type B (HiB) (p 

Recommend Documents

Adverse Event Investigation and Risk Assessment

154 64 12MB

Adverse event profiles of dipeptidyl peptidase-4 inhibitors: data mining of the public version of the FDA adverse event

176 47 320KB

Otoprotective Effect of Cortexin, Cogitum, and Elkar Administered Simultaneously with Netromycin in the Experiment

123 64 606KB

Automating Surveillance for the Analysis of Adverse Event Case Reports

178 45 586KB

Bupropion may increase risk of psoriasis exacerbation

161 11 147KB

Levetiracetam Versus Phenytoin: A Comparison of Efficacy of Seizure Prophylaxis and Adverse Event Risk Following Acute o

153 72 310KB

Dipeptidyl peptidase-4 inhibitors and risk of venous thromboembolism: data mining of FDA adverse event reporting system

144 85 664KB

The risk of nephrotic syndrome with non-VEGF inhibitory antineoplastic drugs: from viewpoint of the adverse event report

136 87 489KB

Determining an Adaptive Exclusion Procedure following Discovery of an Association between the Whole Genome and Adverse D

150 84 12MB

Serious Adverse Event Caused by Combined Target Therapy

165 60 15MB

Adverse Event Reporting and Standardized Medical Terminologies: Strengths and Limitations

179 107 386KB

Combining Social Media and FDA Adverse Event Reporting System to Detect Adverse Drug Reactions

174 10 1016KB